Meeting News
Advertisement
The COMMANDS trial evaluated frontline luspatercept in transfusion-dependent patients with lower-risk MDS and anemia.
CAR-T achieves favorable responses and survival in relapsed or refractory LBCL in both the second- and third-line setting.
The therapy under evaluation by two ongoing studies involves a new accelerated CAR T-cell product manufacturing process.
Fludararabine lymphodepletion is more effective than bendamustine lymphodepletion, but more follow-up is needed to confirm.
The panel moderated by Prithviraj Bose, MD, goes into detail on practical aspects of this agent's use in the clinic.
The expert panel moderated by Dr. Bose looks at noteworthy study work on use of this agent for anemia in myelofibrosis.
Advertisement
Empaneled experts describe their investigations of momelotinib in a continued discussion moderated by Prithviraj Bose, MD.
The expert panel moderated by Prithviraj Bose, MD, tells which research presented at the Meeting they found most exciting.
According to a study, patients with MDS and CMML have dismal clinical outcomes after failure of HMA therapy.
Investigational combinations for MDS appeared to be well tolerated while triplets results in high-grade toxicity.
Phase 2 study results outline benefit of adding venetoclax to intensive chemo in MDS and AML patients.
Moving forward, prospective studies must validate these findings and refine risk stratification tools like the IPSS-R in MDS.
Outcomes for patients with AML and MDS who experience relapse after alloHSCT are poor.
Overall, fedratinib 400 mg daily was a safe MTD for post-HSCT maintenance therapy for participants with MPN.
Some patients with ZRSR2-mutated CCUS had concurrent blood cancers or disorders, and others had protective co-mutation.
Noa Biran, MD reviews a clinical trial of SPd for relapsed or refractory multiple myeloma.
Discussing current clinical trials iand unmet needs in myelofibrosis.
Ziftomenib, venetoclax, and azacitadine is an close to an all-oral regimen for relapsed/refractory acute leukemias.
The benefit of alternating venetoclax regimens was shown in patients with AML and certain AML subgroups.
Continued treatment and follow-up of patients after the interim analysis demonstrate the durability of response to revumenib.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.